Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104.
Adoptive transfer of human TALL-104 killer cells into a dog with metastatic mammary adenocarcinoma resulted in 50% reduction of the largest lung metastasis and stabilization of the other lesions for 10 weeks, accompanied by the development of tumor-specific immune responses. Upon halting cell therapy, the dog developed new lung lesions within 10 weeks and died of slowly progressive disease. TALL-104 cell therapy of mice bearing the dog's tumor xenograft induced 65% reduction of local tumor growth and regression of lung metastases in 100% of the animals. The overall findings indicate the therapeutic potential of TALL-104 cells for canine mammary tumors.
Visonneau
S
S
The Wistar Institute, Philadelphia, PA 19104, USA.
Cesano
A
A
Jeglum
K A
KA
Santoli
D
D
D000818:Animals; D002277:Carcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D003602:Cytotoxicity, Immunologic; D004285:Dogs; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D008285:Major Histocompatibility Complex / Q000276:immunology; D015674:Mammary Neoplasms, Animal / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D009362:Neoplasm Metastasis / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*